Is Insitro profitable in 2026?

No. Insitro has no approved drugs and relies on non-dilutive pharma partnership payments from BMS, Lilly, and Gilead, totaling roughly $140-150M cumulative as self-reported in February 2026. Its lead internal candidate CTRO-1013 only reaches first-in-human trials in 2026, so it remains a pre-revenue-product biotech.

Did Insitro have layoffs?

Yes. Insitro cut 22% of its staff, 63 employees, in a WARN-notice layoff effective March 9, 2025, reducing headcount to roughly 230. The company said the cut extends its cash runway into 2027, per STAT News reporting on May 8, 2025.

Who is Insitro's biggest competitor?

Isomorphic Labs, the Alphabet/DeepMind spinout, is Insitro's most capitalized rival. It raised $2.1B in 2026 at a reported $15-20B valuation and shipped a Drug Design Engine in February 2026, dwarfing Insitro's $400M 2021 Series C and overlapping its pharma partners like Eli Lilly.

Could AI replace Insitro?

Unlikely soon. Insitro's own moat is proprietary wet-lab data, iPSC lines, imaging, and UK Biobank-linked genetics, that frontier AI models cannot replicate without years of physical data generation. Its risk is being outcompeted by better-funded AI-native rivals like Isomorphic Labs, not being replaced by generic AI tools.

Insitro is a privately held company founded in 2018 by Daphne Koller, the Stanford professor and Coursera co-founder. It is venture-backed, with its March 2021 Series C ($400M) led by CPP Investments, valuing the company at roughly $2.4-2.57B; no IPO has occurred as of July 2026.

What is Insitro's lead drug candidate?

CTRO-1013, a siRNA therapy targeting IRS1 for MASLD/MASH, is Insitro's lead internal candidate. As of June 8, 2026, it was in IND-enabling studies with an anti-fibrotic signal reported at the ADA 86th Scientific Sessions, and first-in-human trials were expected later in 2026.

AI companies and labs · United States

Insitro

insitro.com ↗

AI drug discovery company using genomics and cell data to find new medicines.

Losing its protection

Assessed 20 July 2026 · Evidence as of 20 July 2026

The structural protection is eroding.

On the recordSince 20 July 2026 · Checkable from 2026 · Every call on the record Checkpoint: CTRO-1013 first-in-human Phase 1 readout for MASH

The call

Insitro has real data and paying pharma partners, but its cash runway and unproven drug pipeline face a much richer AI rival chasing the same customers.

Insitro is a biotech company that builds computer models and studies human cells to help pharmaceutical companies discover new drugs faster. The company has built a valuable collection of genetic and imaging data linked to patient records, and major drug makers like Bristol Myers Squibb, Eli Lilly, and Gilead are paying to use it. However, Insitro faces two big challenges: it is running low on cash and may need to raise new money soon at a lower valuation than before, and Isomorphic Labs, a well-funded rival backed by Google and DeepMind, is competing for the same pharmaceutical customers with similar technology. The company's success ultimately depends on whether its drugs actually work in patients, which won't be known for several years.

Why

AI pressure: Isomorphic Labs. Alphabet-backed rival uses AlphaFold 3 and its Drug Design Engine to court the same pharma clients with far deeper pockets. Could AI do the core job? Only partly.

Bigger players: Isomorphic Labs (Alphabet/DeepMind). Raised $2.1B at up to $20B valuation and signed Lilly, Novartis, J&J, directly overlapping Insitro's pharma partner list. Could a giant copy it? Probably.

What protects it. Years of proprietary iPSC, genomics, and imaging data tied to UK Biobank that a rival cannot simply buy or scrape.

What would change this call

Insitro announces a new priced funding round in the next 6-12 months. Whether investors value it at, above, or below the 2021 Series C mark.
CTRO-1013 Phase 1 first-in-human readout, expected 2026. Whether the drug platform converts into a clinical clean signal or a stumble.
Any Insitro pharma partner (BMS, Lilly, Gilead) signs a comparable deal with Isomorphic Labs or Recursion. Whether pharma customers are diversifying away from or staying with Insitro.

Key numbers

Runway extends only into 2027 after 22% layoff (2025-05-08)
Isomorphic Labs raised $2.1B at up to $20B valuation (2026-03-22)
BMS paid $10M milestone for new ALS targets (2026-03-23)

Named risks

No priced funding round since 2021; stated runway only extends into 2027. Severity: high
Lead candidate CTRO-1013 unproven, entering first-in-human trials only in 2026. Severity: high
Vastly outcapitalized by Isomorphic Labs ($2.1B raise vs $400M 2021 round). Severity: high
Revenue concentrated in a handful of pharma partners (BMS, Lilly, Gilead). Severity: medium
2025 workforce cut of 22% may strain execution during platform expansion (TherML, CombinAbleAI integration). Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Isomorphic Labs	gaining on	Raised $2.1B at $15-20B valuation in 2026 vs Insitro's flat $2.4B Series C since 2021
Eli Lilly (in-house/partner overlap)	contesting	Partners with both Insitro (Sept 2025) and Isomorphic Labs, splitting pharma AI budget
Insilico Medicine	contesting	Advanced generative-chemistry candidate to Phase 2a with positive IPF data by mid-2026
Recursion Pharmaceuticals	contesting	Public AI drug discovery peer after Exscientia merger, 2024-2025
Xaira Therapeutics	contesting	Founded 2023, raised over $1B, competing for same AI-biotech talent and capital pool

Questions people ask

Is Insitro profitable in 2026?: No. Insitro has no approved drugs and relies on non-dilutive pharma partnership payments from BMS, Lilly, and Gilead, totaling roughly $140-150M cumulative as self-reported in February 2026. Its lead internal candidate CTRO-1013 only reaches first-in-human trials in 2026, so it remains a pre-revenue-product biotech.
Did Insitro have layoffs?: Yes. Insitro cut 22% of its staff, 63 employees, in a WARN-notice layoff effective March 9, 2025, reducing headcount to roughly 230. The company said the cut extends its cash runway into 2027, per STAT News reporting on May 8, 2025.
Who is Insitro's biggest competitor?: Isomorphic Labs, the Alphabet/DeepMind spinout, is Insitro's most capitalized rival. It raised $2.1B in 2026 at a reported $15-20B valuation and shipped a Drug Design Engine in February 2026, dwarfing Insitro's $400M 2021 Series C and overlapping its pharma partners like Eli Lilly.
Could AI replace Insitro?: Unlikely soon. Insitro's own moat is proprietary wet-lab data, iPSC lines, imaging, and UK Biobank-linked genetics, that frontier AI models cannot replicate without years of physical data generation. Its risk is being outcompeted by better-funded AI-native rivals like Isomorphic Labs, not being replaced by generic AI tools.
Who owns Insitro?: Insitro is a privately held company founded in 2018 by Daphne Koller, the Stanford professor and Coursera co-founder. It is venture-backed, with its March 2021 Series C ($400M) led by CPP Investments, valuing the company at roughly $2.4-2.57B; no IPO has occurred as of July 2026.
What is Insitro's lead drug candidate?: CTRO-1013, a siRNA therapy targeting IRS1 for MASLD/MASH, is Insitro's lead internal candidate. As of June 8, 2026, it was in IND-enabling studies with an anti-fibrotic signal reported at the ADA 86th Scientific Sessions, and first-in-human trials were expected later in 2026.

Timeline

2026-06-08Presents CTRO-1013 MASH data at ADA; first-in-human trials expected in 2026
2026-03-23BMS collaboration expanded with ALS-2/ALS-3 targets; receives $10M milestone
2026-02-26Completes brown adipose GWAS study identifying target BAT-01; appoints CPO Joe Hand
2026-01-12Acquires CombinAbleAI, launches unified TherML platform
2025-12-16POSH platform validated in peer-reviewed Nature Communications paper
2025-12-03Appoints Stephen Hitchcock and Vijay Pande as scientific advisors
2025-09Launches Eli Lilly collaboration on ADMET/ChemML models
2025-05-08Reports 22% layoff (63 employees), effective March 9, 2025, extending runway to 2027
2021-03Raises $400M Series C led by CPP Investments
2019-04-16Announces Gilead Sciences collaboration for NASH/MASH, potential value up to $1B

Head to head

Atlas Discovery vs Insitro

Revision history

20 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Safe Superintelligence Inc.Mistral AI Cohere